Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: Pathway-based evaluation of candidate genes

Carcinogenesis

Volumn 31, Issue 5, 2010, Pages 827-833

  Yang, Hannah P ^a,b   Bosquet, Jesus Gonzalez ^a   Li, Qizhai ^a,f   Platz, Elizabeth A ^b   Brinton, Louise A ^a   Sherman, Mark E ^a   Lacey Jr , James V ^a   Gaudet, Mia M ^c   Burdette, Laurie A ^a   Figueroa, Jonine D ^a,g   Ciampa, Julia G ^a   Lissowska, Jolanta ^d   Peplonska, Beata ^e   Chanock, Stephen J ^a   Garcia Closas, Montserrat ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^f CHINESE ACADEMY OF SCIENCES   (China)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; SEX HORMONE; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; CYTOCHROME P450 1A1; ESTROGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLAND; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; MIDDLE AGED; RISK;

ADULT; AGED; AROMATASE; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; GENETIC VARIATION; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ANDROGEN; RISK;

EID: 77952298304     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp328     Document Type: Article

References (72)

1. American Cancer Society. (2009) Cancer Facts & Figures 2009. American Cancer Society, Atlanta, GA.
2. De Vivo,I. et al. (2008) Endometrial cancer. In: Hunter,D. and Trichopoulus,D. (eds) Textbook of Cancer Epidemiology, 2nd edn. Oxford University Press, New York, NY, pp. 468-493.
3. Allen,N.E. et al. (2008) Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr. Relat. Cancer, 15, 485-497.
4. Lukanova,A. et al. (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int. J. Cancer, 108, 425-432.
5. Potischman,N. et al. (1996) Case-control study of endogenous steroid hormones and endometrial cancer. J. Natl Cancer Inst., 88, 1127-1135.
6. Paynter,R.A. et al. (2005) CYP19 (aromatase) haplotypes and endometrial cancer risk. Int. J. Cancer, 116, 267-274.
7. Haiman,C.A. et al. (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res., 67, 1893-1897.
8. Setiawan,V.W. et al. (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol. Biomarkers Prev., 18, 242-247.
9. McGrath,M. et al. (2006) Androgen receptor polymorphisms and endometrial cancer risk. Int. J. Cancer, 118, 1261-1268.
10. Yang,H.P. et al. (2009) Genetic variation in the androgen receptor gene and endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev., 18, 585-589.
11. Doherty,J.A. et al. (2005) Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol. Biomarkers Prev., 14, 357-366.
12. Hirata,H. et al. (2008) COMT polymorphisms affecting protein expression are risk factors for endometrial cancer. Mol. Carcinog., 47, 768-774.
13. McGrath,M. et al. (2004) Cytochrome P450 1B1 and catechol-Omethyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis, 25, 559-565.
14. Rebbeck,T.R. et al. (2006) Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J. Natl Cancer Inst., 98,1311-1320.
15. Tao,M.H. et al. (2006) Cytochrome P450 1B1 and catechol-o-methyltransferase genetic polymorphisms and endometrial cancer risk in Chinese women. Cancer Epidemiol. Biomarkers Prev., 15, 2570-2573.
16. Esinler,I. et al. (2006) CYP1A1 gene polymorphism and risk of endometrial hyperplasia and endometrial carcinoma. Int. J. Gynecol. Cancer, 16, 1407-1411.
17. Esteller,M. et al. (1997) Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis, 18, 2307-2311.
18. Esteller,M. et al. (1997) Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br. J. Cancer, 75, 1385-1388.
19. Hirata,H. et al. (2008) CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer, 112, 1964-1973.
20. McGrath,M. et al. (2007) Cytochrome P450 1A1, cigarette smoking, and risk of endometrial cancer (United States). Cancer Causes Control, 18, 1123-1130.
21. Mikhailova,O.N. et al. (2006) Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics, 6, 189-193.
22. Seremak-Mrozikiewicz,A. et al. (2005) CYP1A1 alleles in female genital cancers in the Polish population. Eur. J. Obstet. Gynecol. Reprod. Biol., 118, 246-250.
23. Sugawara,T. et al. (2003) CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int. J. Gynecol. Cancer, 13, 785-790.
24. Chu,W. et al. (2007) Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis, 28, 2139-2142.
25. Aban,M. et al. (2006) CYP17 genetic polymorphism in patients with endometrial hyperplasia and cancer. Int. J. Gynecol. Cancer, 16 (suppl. 1), 448-451.
26. Berstein,L.M. et al. (2004) CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett., 207, 191-196.
27. Gaudet,M.M. et al. (2008) Genetic variation in CYP17 and endometrial cancer risk. Hum. Genet., 123, 155-162.
28. Haiman,C.A. et al. (2001) A polymorphism in CYP17 and endometrial cancer risk. Cancer Res., 61, 3955-3960.
29. McKean-Cowdin,R. et al. (2001) Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res., 61, 848-849.
30. Olson,S.H. et al. (2007) Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am. J. Epidemiol., 165, 235-245.
31. Olson,S.H. et al. (2008) Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control, 19, 955-963.
32. Szyllo,K. et al. (2006) The polymorphisms of the CYP17 and CYP19 genes in endometrial cancer patients. Pol. J. Pathol., 57, 35-40.
33. Szyllo,K. et al. (2006) The T/C polymorphism of the CYP17 gene and G/A polymorphism of the CYP19 gene in endometrial cancer. J. Exp. Clin. Cancer Res., 25, 411-416.
34. Tao,M.H. et al. (2007) Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol. Biomarkers Prev., 16, 943-949.
35. Rylander-Rudqvist,T. et al. (2004) Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev., 13, 1515-1520.
36. Sasaki,M. et al. (2003) CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res., 63, 3913-3918.
37. Ashton,K. et al. (2009) Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG, 116, 1053-1061.
38. Iwamoto,I. et al. (2003) Association of estrogen receptor alpha and beta3adrenergic receptor polymorphisms with endometrial cancer. Obstet. Gynecol., 102, 506-511.
39. Sasaki,M. et al. (2002) Polymorphisms of estrogen receptor alpha gene in endometrial cancer. Biochem. Biophys. Res. Commun., 297, 558-564.
40. Wedren,S. et al. (2008) Estrogen receptor alpha gene polymorphism and endometrial cancer risk-a case-control study. BMC Cancer, 8, 322.
41. Weiderpass,E. et al. (2000) Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis, 21, 623-627.
42. Setiawan,V.W. et al. (2004) Estrogen receptor beta (ESR2) polymorphisms and endometrial cancer (United States). Cancer Causes Control, 15, 627-633.
43. Dai,Q. et al. (2007) Interaction of soy and 17beta-HSD1 gene polymorphisms in the risk of endometrial cancer. Pharmacogenet. Genomics, 17, 161-167.
44. Setiawan,V.W. et al. (2004) HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol. Biomarkers Prev., 13, 213-219.
45. De Vivo,I. et al. (2002) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Natl Acad. Sci. USA, 99, 12263-12268.
46. Dossus,L. et al. (2006) No association between progesterone receptor gene +331G/A polymorphism and endometrial cancer. Cancer Epidemiol. Biomarkers Prev., 15, 1415-1416.
47. Junqueira,M.G. et al. (2007) Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development. Int. J. Gynecol. Cancer, 17, 229-232.
48. Xu,W.H. et al. (2009) Association of the progesterone receptor gene with endometrial cancer risk in a Chinese population. Cancer, 115, 2693-2700
49. Kataoka,N. et al. (2007) Association of endometrial cancer risk with a functional polymorphism (Asp(327)Asn) in the sex hormone-binding globulin gene. Cancer, 109, 1296-1302.
50. Xu,W.H. et al. (2008) The Asp(327)Asn polymorphism in the sex hormonebinding globulin gene modifies the association of soy food and tea intake with endometrial cancer risk. Nutr. Cancer, 60, 736-743.
51. Deming,S.L. et al. (2008) UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev., 17, 563-570.
52. Duguay,Y. et al. (2004) The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res., 64, 1202-1207.
53. McGrath,M. et al. (2009) Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenet. Genomics, 19, 239-243.
54. Brinton,L.A. et al. (2007) Reproductive risk factors for endometrial cancer among Polish women. Br. J. Cancer, 96, 1450-1456.
55. Miller,W.L. (2008) Steroidogenic enzymes. Endocr. Dev., 13, 1-18.
56. Payne,A.H. et al. (2004) Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev., 25, 947-970.
57. Stanczyk,F.Z. et al. (2003) Biosynthesis, transport, and metabolism of steroid hormones. In: Henderson,B.E., Ponder,B.A. and Ross,R.K. (eds) Hormones, Genes, and Cancer. Oxford University Press, New York, NY, pp. 12-37.
58. Ashburner,M. et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet., 25, 25-29.
59. Gene Ontology Consortium. (2006) The Gene Ontology (GO) project in 2006. Nucleic Acids Res., 34, D322-D326.
60. Aoki,K.F. et al. (2005) Using the KEGG database resource. Curr. Protoc. Bioinformatics, Chapter 1, Unit 1.12.
61. Carlson,C.S. et al. (2004) Selecting a maximally informative set of singlenucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet., 74, 106-120.
62. Yu,K. et al. (2009) Pathway analysis by adaptive combination of P-values. Genet. Epidemiol, 33, 700-709.
63. Scheet,P. et al. (2006) A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am. J. Hum. Genet., 78, 629-644.
64. Yu,Z. et al. (2007) Sequential haplotype scan methods for association analysis. Genet. Epidemiol., 31, 553-564.
65. Li,Y. et al. (2007) Association mapping via regularized regression analysis of single-nucleotide-polymorphism haplotypes in variable-sized sliding windows. Am. J. Hum. Genet., 80, 705-715.
66. Schaid,D.J. et al. (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet., 70, 425-434.
67. Giudice,L.C. (2006) Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract. Res. Clin. Endocrinol. Metab., 20, 235-244.
68. Watanabe,K. et al. (1995) Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am. J. Pathol., 146, 491-500.
69. Matsumoto,M. et al. (2008) Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr. Relat. Cancer, 15, 451-463.
70. Eliassen,A.H. et al. (2008) Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv. Exp. Med. Biol., 630, 148-165.
71. Ito,K. et al. (2002) Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. Int. J. Cancer, 99, 652-657.
72. Dunning,A.M. et al. (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J. Natl Cancer Inst., 96, 936-945.